Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.
OBJECTIVE
To investigate the statistical relationship between the OM8-30 health-related quality of life measure for children with otitis media with effusion (OME) and measures of health utility (Health Utilities Index [HUI] Mark 3 and Mark 2) and to develop models to estimate HUI3 and HUI2 health utilities from OM8-30 scores.


METHODS
A placebo-controlled, randomised trial (GNOME) evaluating intranasal mometasone in 217 children with OME provided concurrent responses to OM8-30 and HUI at three time points. Ordinary least squares (OLS), generalised linear models and two-step regression analyses were used to predict HUI3 and HUI2 utilities based on OM8-30 facet and domain scores.


RESULTS
OLS models including all nine OM8-30 facets with or without predicted hearing level (HL) produced the best predictions of HUI3 utilities (mean absolute error: 0.134 with HL and 0.132 without; R(2): 0.63 with HL and 0.596 without). An OLS model predicting HUI3 utilities based on the two OM8-30 domain scores, reported hearing difficulties, predicted HL, age and sex also produced accurate predictions.


CONCLUSIONS
Regression equations predicting HUI3 and HUI2 utilities based on OM8-30 facet and domain scores have been developed. These provide an empirical basis for estimating quality-adjusted life years (QALYs) for interventions in children with OME.
Dakin
Helen
H
Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Oxford, UK. Helen.dakin@dphpc.ox.ac.uk
Petrou
Stavros
S
Haggard
Mark
M
Benge
Sarah
S
Williamson
Ian
I
D000281:Administration, Intranasal; D000704:Analysis of Variance; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D000068656:Mometasone Furoate; D010034:Otitis Media with Effusion / Q000188:drug therapy* / Q000523:psychology; D011244:Pregnadienediols / Q000008:administration & dosage*; D011594:Psychometrics; D019057:Quality-Adjusted Life Years; D012016:Reference Values; D012720:Severity of Illness Index; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires
D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate